Screener
Ultragenyx Pharmaceutical RARE Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's other non-current liabilities?
- Ultragenyx Pharmaceutical (RARE) reported other non-current liabilities of $41M in Q2 2026.
- How has Ultragenyx Pharmaceutical's other non-current liabilities changed year-over-year?
- Ultragenyx Pharmaceutical's other non-current liabilities increased by 135.7% year-over-year, from $17.4M to $41M.
- What is the long-term trend for Ultragenyx Pharmaceutical's other non-current liabilities?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's other non-current liabilities has grown at a 43.0% compound annual growth rate (CAGR), from $7.35M to $44M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Ultragenyx Pharmaceutical's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude